Fabio Salvatore Macaluso

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11287249/publications.pdf

Version: 2024-02-01

25 papers	1,128 citations	623734 14 h-index	580821 25 g-index
25 all docs	25 docs citations	25 times ranked	2384 citing authors

#	Article	IF	Citations
1	Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19. Inflammatory Bowel Diseases, 2023, 29, 217-221.	1.9	9
2	Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?. Gastroenterology, 2021, 160, 1877-1878.	1.3	6
3	A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 105-111.	2.8	14
4	Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110106.	3.2	13
5	Vaccinations in patients with inflammatory bowel disease. Digestive and Liver Disease, 2021, 53, 1539-1545.	0.9	12
6	Effectiveness and safety of Ustekinumab for the treatment of Crohnâ€™s disease in real-life experiences: a meta-analysis of observational studies. Expert Opinion on Biological Therapy, 2020, 20, 193-203.	3.1	33
7	Effectiveness of Ustekinumab on Crohnâ€˜s Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). Expert Opinion on Biological Therapy, 2020, 20, 1381-1384.	3.1	8
8	COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data. Digestive and Liver Disease, 2020, 52, 1222-1227.	0.9	38
9	JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease. Current Drug Metabolism, 2020, 21, 247-255.	1.2	4
10	Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. Digestive and Liver Disease, 2019, 51, 613-620.	0.9	14
11	Anti-interleukin-12 and anti-interleukin-23 agents in Crohnâ€™s disease. Expert Opinion on Biological Therapy, 2019, 19, 89-98.	3.1	31
12	How clinicians and pathologists interact concerning inflammatory bowel disease in Italy: An IG-IBD survey. Digestive and Liver Disease, 2018, 50, 734-736.	0.9	3
13	Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease. Journal of Infection, 2017, 74, 433-441.	3.3	28
14	Screening of colorectal cancer: present and future. Expert Review of Anticancer Therapy, 2017, 17, 1131-1146.	2.4	123
15	Hepatitis C Virus Infection Is Associated With IncreasedÂCardiovascular Mortality: A Meta-Analysis of Observational Studies. Gastroenterology, 2016, 150, 145-155.e4.	1.3	201
16	The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. Hepatology, 2015, 62, 1101-1110.	7.3	183
17	Genetic background in nonalcoholic fatty liver disease: A comprehensive review. World Journal of Gastroenterology, 2015, 21, 11088.	3.3	66
18	Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. Future Microbiology, 2015, 10, 977-988.	2.0	2

#	Article	IF	Citations
19	Cardiovascular diseases and HCV infection: a simple association or more?. Gut, 2014, 63, 369-375.	12.1	67
20	Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. Clinical Gastroenterology and Hepatology, 2014, 12, 878-884.e1.	4.4	13
21	Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. Journal of Hepatology, 2014, 61, 523-529.	3.7	67
22	Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. Journal of Hepatology, 2013, 59, 1169-1176.	3.7	33
23	Herbal hepatotoxicity: a hidden epidemic. Internal and Emergency Medicine, 2013, 8, 13-22.	2.0	61
24	Serum Î³-glutamyl Transferase Levels, Insulin Resistance and Liver Fibrosis in Patients with Chronic Liver Diseases. PLoS ONE, 2012, 7, e51165.	2.5	29
25	Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver International, 2011, 31, 507-515.	3.9	70